65,437 trials
Chronic Kidney Disease
Primary: Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) — 171.3; 167.5; 87.14; 149.0 ng*h/mL
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects
Covid19 · Progression
Primary: Number of Participants With Progression — 5; 11 Participants
Schizophrenia · Metabolic Syndrome X · Insulin Resistance
Primary: Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min) — 0.072; 0.407 (1/mU/L) x 1/Min — p=0.228
Fungal Infections · Invasive Pulmonary Aspergillosis
Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001
Traumatic Brain Injury
Primary: Baseline Measures Before Treatment
Healthy Volunteers
Primary: Treatment B vs Treatment A (Part 1), Combined Molar Exposure for Cmax: Maximum Observed Plasma Concentration of TAK-788, AP32960, and AP32914 — 13.7; 39.2 nM
Bile Acid Synthesis Defect
Primary: Change in Atypical Urinary Bile Acid Excretion by FAB-MS (Fast-Atom-Bombardment Ionization-Mass Spectrometry) — 25; 6; 10; 10 Participants
Septal Defect, Atrial
Primary: Number of Subjects With 6-Month Composite Clinical Success — 332 Participants — p=<0.0001
Body Temperature · Thermosensing · Temperature
Primary: Body Temperature Difference in Degrees Celsius — -0.28 Degrees Celsius — p=0.69
Diabetes Mellitus
Primary: Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI — 93.2 percentage of paired readings
Hepatitis C Virus Infection
Primary: Percentage of Participants Experiencing Treatment Emergent Adverse Events — 25.0; 14.3; 16.7; 13.3 percentage of participants
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
Atrial Fibrillation
Primary: Percent of Subjects Free From Treatment Failure at 12 Months After the Pulmonary Vein Isolation (PVI) Ablation Procedure. — 54.8 percentage of participants — p=<0.001
Dental Caries
Primary: Observed Iodine Tmax — 1.7 hours